Biotech IV Monitor

LNTH — Lantheus Holdings Inc.

$6.8B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Lantheus Holdings Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is August 2027.

Next readoutAugust 2027in ~9 months
Upcoming readouts32 Phase 3
Market cap$6.8B
Cash & investments$684Mas of Sep 30, 2026
Recent 8-K filings3latest 2026-11-10

Upcoming readouts

Phase 1/2 LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma · NCT07357519
August 2027
Recruiting
Phase 3 [18F]PI-2620
Alzheimer Disease · NCT05641688
March 2028
Recruiting
Phase 2/3 [68Ga]-LNTH-2401
Prostate Cancer · NCT07831824
September 2029
Recruiting

Cash position

Lantheus Holdings Inc. reported $684M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $22M for that quarter.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-10
8-K Results of Operations — earnings, may carry pipeline updates2026-11-05
8-K Other Events — often topline trial data2026-10-22

Companies working on similar indications

Discussion

No messages yet. If you follow LNTH, you can start the conversation.
Track LNTH in real time
See live implied volatility for LNTH and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on LNTH
Contact — questions or corrections about LNTH: dukeupt@gmail.com